Working… Menu
Trial record 36 of 69 for:    ORLISTAT

Efficacy and Safety of ATL-962 in Obese Diabetics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00156897
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : August 29, 2006
Information provided by:

Brief Summary:
The purpose of this study is to investigate whether ATL-962 induces weight loss in diabetic patients and whether its safety and tolerability profile is superior to that of orlistat in such patients

Condition or disease Intervention/treatment Phase
Non-Insulin-Dependent Diabetes Mellitus Obesity Drug: ATL-962 Drug: Orlistat Phase 2

Detailed Description:

Obesity is a significant and increasing clinical problem. There is a need for effective therapeutic agents to help people reduce weight. ATL-962 is a lipase inhibitor which could reduce the amount of fat absorbed from a person's diet, leading to weight reduction.

In this study patients with Type II diabetes who are clinically obese will receive ATL-962 at one of three dose levels, or placebo, or orlistat (another lipase inhibitor). The study will investigate the amount of weight lost after 12 weeks' treatment and will compare the safety and tolerability profile of ATL-962 and orlistat.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Multicentre Double Blind Placebo Controlled Parallel Group Dose Ranging Study of ATL-962 to Assess Weight Loss, Safety and Tolerability in Obese Patients With Type II Diabetes Being Treated With Metformin, in Comparison With Orlistat
Study Start Date : December 2004
Study Completion Date : October 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Weight Control
Drug Information available for: Orlistat

Primary Outcome Measures :
  1. Absolute weight loss compared to baseline

Secondary Outcome Measures :
  1. Proportion of patients achieving 5% or 10% weight loss
  2. Changes in waist circumference
  3. Changes in lipid profiles
  4. Changes in markers of diabetes
  5. Incidence of gastrointestinal adverse effects
  6. Changes in other safety parameters

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type II diabetes
  • Body mass index 28-45kg/m2
  • HbA1c 6%-10%

Exclusion Criteria:

  • Significant weight loss in the previous 3 months
  • Weight gain during the run-in period
  • Other serious systemic conditions, except controlled hypertension, mild asthma, and primary hypothyroidism
  • History of GI disorders
  • Previous surgery for weight loss

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00156897

Layout table for location information
Aalborg Sygehus Nord
Aalborg, Denmark
Aarhus University Hospital
Aarhus, Denmark, DK-8000
Bispebjerg Hospital
Copenhagen, Denmark, DK-2400
Gentofte Hospital
Hellerup, Denmark, DK-2900
Hvidovre Hospital
Hvidovre, Denmark, DK-2650
Odense University Hospital
Odense, Denmark
Lääkärikeskus Minerva
Eura, Finland, 27510
Obesity Research Unit
Helsinki, Finland, 00100
Suomen Terveystalo
Jyvaskyla, Finland, 40100
Oy Foodfiles Limited
Kuopio, Finland
Oulun Diakonissalaitos
Oulu, Finland, 90100
University of Oulu
Oulu, Finland
Turku University Hospital
Turku, Finland, 20520
Den Bosch Ziekenhuis, Netherlands
DN de Bilt, Netherlands
Zeikenhuisgroep Twente
Hengelo, Netherlands
Nederlandse Obesitas Klinik
Hilversum, Netherlands
Sint Franciscus Gasthuis
Rotterdam, Netherlands
Sahlgrenska University Hospital
Goteborg, Sweden
Linkoping University Hospital
Linkoping, Sweden
Karolinsaka University Hospital
Stockholm, Sweden
Norrlands Universitetssjukhus
Umea, Sweden
Samariterhemmets Sjukhus
Uppsala, Sweden
United Kingdom
Aberdeen Royal Infirmary
Aberdeen, United Kingdom
Royal United Hospital
Bath, United Kingdom
Clinical Research Centre Edgbaston
Birmingham, United Kingdom
Walsgrave Hospital
Coventry, United Kingdom
Glasgow Royal Infirmary
Glasgow, United Kingdom
Clinical Research Centre, Crosby
Liverpool, United Kingdom
Liverpool University Hospital
Liverpool, United Kingdom
Queen Mary's School of Medicine & Dentistry
London, United Kingdom, E1 2AA
Hammersmith Hospital
London, United Kingdom
Luton & Dunstable Hospital
Luton, United Kingdom
Clinical Research Centre
Manchester, United Kingdom
James Cook University Hospital
Middlesborough, United Kingdom
Royal Shrewsbury Hospital
Shrewsbury, United Kingdom
Clinical Research Centre
Wigan, United Kingdom
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Peter Kopelman Queen Mary's School of Medicine & Dentistry, London, UK

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information Identifier: NCT00156897     History of Changes
Other Study ID Numbers: ATL-962/175/CL
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: August 29, 2006
Last Verified: August 2006
Keywords provided by Alizyme:
Non-insulin-dependent diabetes mellitus
Type II diabetes
Lipase inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Obesity Agents
Lipid Regulating Agents